GIGABYTE
24.6.2021 12:47:12 CEST | Business Wire | Press release
GIGABYTE, a world leader in computer technology, is excited to be part of MWC (Mobile World Congress) to present its products and insights on Edge computing , and be joined by innovators and decision-makers who will shape the future of 5G deployments and 6G planning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005477/en/
GIGABYTE presents a series of servers that are “short and sweet”, and available in either x86 or Arm platforms to support diverse applications. Not only are these Edge servers shortened to depths ranging from only 400-600mm to fit in more environments for telecom deployments, but also ready to serve as HPCs to handle challenging workloads for AI and data processing that are closer to users’ applications.
- E152-ZE0 - Supports 3rd Gen AMD EPYC 7003 and 7002 processors, is extremely short with 400mm in depth, comes with 8 DIMM slots, and supports two U.2 NVMe SSDs. The E152 chamber for dual-slot GPUs can also be used for two single-slot cards operating at Gen4 x16, and two low-profile expansion slots on the front to provide user with powerful performance and flexibility for implementation.
- E162-220 - Designed for 3rd Gen Intel Xeon Scalable processors and has 16 DIMMs for industry standard 8-channel memory, and supports two U.2 SSDs and three M.2 connectors onboard with Gen4 PCIe transmission. All I/Os are designed in the same direction, making it suitable not only for installation in data centers, but also for deployment in base stations to provide 5G MEC or edge computing for services.
- E251-U70 - The first GIGABYTE edge server designed for 2nd Gen Intel Xeon Scalable processors, supporting six 2.5” SATA/SAS bays on the front-left, and a dual-slot GPU plus a FHFL single-slot card on the front-right. Notably, this server was chosen by NVIDIA Aerial Developer Kit for development and deployment of vRAN stack. E251-U71, a SKU variant that is NEBS design ready, is designed for extreme conditions such as high temperature, humidity or altitude.
- E252-P30 – Built for workloads on Arm architecture and uses Ampere Altra processors with up to 80 cores and 16 DIMMS for a wealth of possibilities in the cloud, the server is a viable option when considering TCO. It has six SSDs bays and lots of expansion slots for low-profile accelerators, storage, or networking.
The “short”ness of GIGABYTE Edge servers’ chassis and the “sweet”ness of its performance capabilities will prove to be indispensable equity in telecommunications, as the success in 5G deployments demands a widespread of MEC networks that are both closely-and-intelligently-connected.
GIGABYTE is an engineer, visionary, and leader in the tech world that uses its hardware expertise, patented innovations, and industry leadership to create, inspire, and advance. With over 30 years of celebrated experience, GIGABYTE is pleased to be the backbone of the IT infrastructure and provide the industry with data center expertise and cutting-edge server products that can accelerate scientific and technological breakthroughs.
https://www.mwcbarcelona.com/exhibitors/gigabyte-technology
See more presentations: https://www.gigabyte.com/Tech-Tune-In
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005477/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 11:30:00 CET | Press release
Second limited-edition WHOOP x SR_A collection brings “performance for life” to new WHOOP bands, technical apparel, outerwear, and accessories designed for movement across city and rural environments. WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural wo
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 11:28:00 CET | Press release
Oral-B iO helps you avoid new tooth and gum issues—and if you have existing gum problems, it can resolve them quicker than a manual toothbrush. Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom